Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 19 November 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Disease burden of Hepatitis B-related hepatocellular carcinoma

This month's issue of the Journal of Viral Hepatitis examines Hepatitis B-related hepatocellular carcinoma.

News image

fiogf49gjkf04

Worldwide, 350 million people are chronically infected with hepatitis B virus  who are at greater risk of hepatocellular carcinoma compared with uninfected people.

Dr Nguyen and colleagues from Australia explored the epidemiology and disease burden of Hepatits B-related hepatocellular carcinoma.

The relative risks of hepatocellular carcinoma among people infected with hepatitis B virus ranges from 5 to 49 in case–control studies and from 7 to 98 in cohort studies.

More than 50% of hepatocellular carcinoma cases worldwide, and 70–80% of hepatocellular carcinoma cases in highly hepatitis B virus endemic regions are attributable to hepatitis B virus.

The team found that the incidence of hepatocellular carcinoma (per 100 000 person/year) among people with chronic hepatitis B virus infection ranges from 400 to 800 in male and from 120 to 180 in female.
Survival rates of hepatitis B virus-related hepatocellular carcinoma  ranged from 36% to 67% after 1 year.

Journal of Viral Hepatitis

Factors associated with increased risk of hepatocellular carcinoma  include demographic characteristics, and lifestyles.

In addition, viral factors (genotype C, D F, high level of hepatitis B virus  DNA, core/precore mutation), clinical factors (cirrhosis, elevated alpha-fetoprotein and alanine aminotransferase) increased the risk.

The researchers found that hepatitis B virus-related hepatocellular carcinoma has extremely poor prognosis with median survival less than 16 months.

Survival rates of hepatitis B virus-related hepatocellular carcinoma  ranged from 36% to 67% after 1 year, and from 15% to 26% after 5 year of diagnosis.

Older age, liver function impairment, vascular invasion, tumour aggressiveness and elevated AFP are associated with hepatocellular carcinoma  survival.

Global burden of hepatitis B virus -related liver disease is still a major challenge for public health in the 21st century.

The team found that while decreases in incidence of hepatitis B virus  infection have been observed in birth cohorts following the introduction of universal infant hepatitis B virus vaccination program.

Hepatitis B virus-related hepatocellular carcinoma incidence is projected to increase for at least 2 decades.

This projected increase is because of the high prevalence of chronic hepatitis B virus infection, and prolonged latency to hepatocellular carcinoma  development.

Dr Nguyen's team concluded, “To reduce hepatitis B virus-related hepatocellular carcinoma continued expansion of universal infant hepatitis B virus vaccination is required along with antiviral therapy targeted to those individuals at highest risk of hepatocellular carcinoma.”

“Broad public health strategies should include routine testing to identify chronic hepatitis B virus infection, improved health infrastructures including human resource to provide diagnosis and treatment assessment.”

J Vir Hep 2009: 16(7): 453-63
15 June 2009

Go to top of page Email this page Email this page to a colleague

 17 November 2017 
Food elimination diets for treatment of adults with eosinophilic esophagitis
 17 November 2017 
PPI use and cognitive function in women
 17 November 2017 
Predicting microscopic colitis
 16 November 2017 
NAFLD-hepatocellular carcinoma and survival after orthotopic liver transplant
 16 November 2017 
Prepregnancy obesity and severe maternal morbidity
 16 November 2017 
Celiac disease screening in adult first-degree relatives
 15 November 2017 
Breastfeeding and the risk of IBD
 15 November 2017 
Medication nonadherence and health care costs
 15 November 2017 
Predicting recurrence after curative rectal cancer surgery
 14 November 2017 
HBV/HCV coinfection and cirrhosis
 14 November 2017 
Sexual dysfunction after rectal cancer surgery
 14 November 2017 
Eosinophilic gastroenteritis and colitis
 13 November 2017 
GI bleeding in patients taking non–vitamin K antagonist oral anticoagulants
 13 November 2017 
Genetic polymorphisms, fatty acids and ulcerative colitis
 13 November 2017 
Flares after immunomodulator withdrawal in Crohn's
 10 November 2017 
Thiopurines vs TNF and lymphoma risk in IBD
 10 November 2017 
Drug monitoring of anti-tumour necrosis factor therapy in IBD
 10 November 2017 
Treatment decisions for older patients with colorectal cancer
 09 November 2017 
Quality standards in upper gastrointestinal endoscopy
 09 November 2017 
Irradiated rectal cancer and chemoradiotherapy
 09 November 2017 
Environmental factors and IBD
 08 November 2017 
Prophylaxis of spontaneous bacterial peritonitis
 08 November 2017 
Socioeconomic characteristics in diverticular disease
 08 November 2017 
Optimal management of postoperative Crohn's disease
 07 November 2017 
Community Screening for Helicobacter pylori
 07 November 2017 
Early readmission in IBD patients
 07 November 2017 
Mesocolic excision for colon cancer
 06 November 2017 
Food elimination diet for children with eosinophilic esophagitis
 06 November 2017 
Biologic agents and obesity in children with IBD
 06 November 2017 
Liver cancer burden despite extensive use of antiviral agents
 03 November 2017 
Statins and mortality in chronic viral hepatitis
 03 November 2017 
Propofol for outpatient colonoscopy
 03 November 2017 
Asthma and IBD development
 02 November 2017 
Diverticulitis and emergency department burden
 02 November 2017 
Rural residence and risk of IBD
 02 November 2017 
Sexual functioning in Hep C
 01 November 2017 
Heartburn relief in adolescents with GERD
 01 November 2017 
Barriers to hepatitis C treatment
 01 November 2017 
Autoimmune pancreatitis in children
 31 October 2017 
Surveillance in ulcerative colitis and Crohn’s disease
 31 October 2017 
Endoscopic indices of disease activity for Crohn’s
 31 October 2017 
Follow-up of positive results on fecal blood tests
 30 October 2017 
Local recurrence after curative rectal cancer surgery
 30 October 2017 
Low-flow ascites pump in refractory cirrhosis
 30 October 2017 
Medical therapy of patients with pediatric-onset IBD
 27 October 2017 
NAFLD in advanced fibrosis in the USA
 27 October 2017 
Early readmission in cirrhosis after bacterial infections
 26 October 2017 
Predicting response to anti-TNF therapy in Crohn's
 26 October 2017 
Conversion to open laparotomy in rectal cancer
 25 October 2017 
Conversion of colonoscopy to sigmoidoscopy
 25 October 2017 
Fecal microbiota transplantation
 25 October 2017 
Rifaximin and survival in hepatic encephalopathy
 24 October 2017 
Eosinophilic esophagitis with swallowed topical corticosteroids
 24 October 2017 
Meta-analysis in nutritiona research
 23 October 2017 
NAFLD-related hepatocellular carcinoma in liver resection
 23 October 2017 
Outcome of hepatic sarcoidosis
 20 October 2017 
Hospital readmissions reduction program
 20 October 2017 
Conversion of planned colonoscopy to sigmoidoscopy
 19 October 2017 
Fecal immunochemical tests in colorectal cancer screening
 19 October 2017 
Current management of chylous ascites

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us